1. Home
  2. LION vs GLPG Comparison

LION vs GLPG Comparison

Compare LION & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lionsgate Studios Corp.

LION

Lionsgate Studios Corp.

HOLD

Current Price

$9.18

Market Cap

2.4B

ML Signal

HOLD

Logo Galapagos NV

GLPG

Galapagos NV

HOLD

Current Price

$33.04

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LION
GLPG
Founded
1997
1999
Country
United States
Belgium
Employees
N/A
N/A
Industry
Movies/Entertainment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.1B
IPO Year
N/A
2005

Fundamental Metrics

Financial Performance
Metric
LION
GLPG
Price
$9.18
$33.04
Analyst Decision
Buy
Hold
Analyst Count
10
4
Target Price
$9.11
$31.33
AVG Volume (30 Days)
2.9M
86.8K
Earning Date
02-05-2026
02-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,858,000,000.00
$336,643,201.00
Revenue This Year
N/A
$1.76
Revenue Next Year
$22.30
$0.49
P/E Ratio
N/A
N/A
Revenue Growth
21.18
10.31
52 Week Low
$5.55
$22.36
52 Week High
$9.25
$37.78

Technical Indicators

Market Signals
Indicator
LION
GLPG
Relative Strength Index (RSI) 76.84 62.59
Support Level $8.21 $30.73
Resistance Level $9.25 $33.23
Average True Range (ATR) 0.43 0.59
MACD 0.09 0.18
Stochastic Oscillator 92.52 91.22

Price Performance

Historical Comparison
LION
GLPG

About LION Lionsgate Studios Corp.

Lionsgate Studios Corp is a motion picture and television studio operations aligned with the STARZ premium subscription platform to bring a varied portfolio of entertainment to consumers around the world. The group has two reportable business segments: the Motion Picture and Television Production reportable segments. Motion Picture consists of the development and production of feature films, the acquisition of North American and world-wide distribution rights. Television Production consists of the development, production, and world-wide distribution of television productions, including television series, television movies and mini-series, and non-fiction programming.

About GLPG Galapagos NV

Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.

Share on Social Networks: